578 related articles for article (PubMed ID: 22565619)
1. Novel oral anticoagulants--key messages for the angiologist.
Haas S; Spannagl M; Schellong SM
Vasa; 2012 May; 41(3):177-91. PubMed ID: 22565619
[TBL] [Abstract][Full Text] [Related]
2. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
3. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J
Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100
[No Abstract] [Full Text] [Related]
4. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY
Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465
[TBL] [Abstract][Full Text] [Related]
5. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
Akwaa F; Spyropoulos AC
Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Skjøth F; Larsen TB; Rasmussen LH; Lip GY
Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
[TBL] [Abstract][Full Text] [Related]
7. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Berman JP; Halperin JL
Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
[TBL] [Abstract][Full Text] [Related]
8. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
9. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
10. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
Gong IY; Kim RB
Can J Cardiol; 2013 Jul; 29(7 Suppl):S24-33. PubMed ID: 23790595
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
12. Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
Int J Clin Pharmacol Ther; 2015 Mar; 53(3):211-9. PubMed ID: 25295718
[TBL] [Abstract][Full Text] [Related]
13. Perioperative management of patients on new oral anticoagulants.
Lai A; Davidson N; Galloway SW; Thachil J
Br J Surg; 2014 Jun; 101(7):742-9. PubMed ID: 24777590
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Lenchus JD
Hosp Pract (1995); 2013 Feb; 41(1):49-60. PubMed ID: 23466967
[TBL] [Abstract][Full Text] [Related]
15. Acute management of bleeding in patients on novel oral anticoagulants.
Siegal DM; Crowther MA
Eur Heart J; 2013 Feb; 34(7):489-498b. PubMed ID: 23220847
[TBL] [Abstract][Full Text] [Related]
16. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
[TBL] [Abstract][Full Text] [Related]
17. Bleeding and antidotes in new oral anticoagulants.
Majeed A; Schulman S
Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
[TBL] [Abstract][Full Text] [Related]
18. Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
Blann AD
Br J Biomed Sci; 2014; 71(4):158-67. PubMed ID: 25562993
[TBL] [Abstract][Full Text] [Related]
19. Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Douketis J; Bell AD; Eikelboom J; Liew A
Can Fam Physician; 2014 Nov; 60(11):989-95. PubMed ID: 25392438
[TBL] [Abstract][Full Text] [Related]
20. [New clinical perspectives in the management of oral direct anticoagulant agents].
Marco P; Zamorano JL; Chana F; Llau JV
Med Clin (Barc); 2014 Feb; 142(4):171-8. PubMed ID: 23866969
[No Abstract] [Full Text] [Related]
[Next] [New Search]
